1. For the working group ‘Equity in Access to Treatment of Rheumatoid Arthritis in Europe’. Inequities in access to biologic and synthetic DMARDs across 46 European countries;Putrik;Ann Rheum Dis,2014
2. The economics of biosimilars;Blackstone;Am Health Drug Benefits,2013
3. US Food and Drug Administration. Biosimilar product information. https://www.fda.gov/drugs/biosimilars/biosimilar-product-information. Accessed September 24, 2021.
4. Brill A. and Robinson C. Lessons for the United States from Europe's biosimilar experience. June 2020. https://biosimilarscouncil.org/wp-content/uploads/2020/06/EuropeBiosimilars_June_2020.pdf. Accessed August 25, 2020.
5. European Medicines Agency. Medicines. https://www.ema.europa.eu/en/medicines/field_ema_web_categories%253Aname_field/Human/ema_group_types/ema_medicine/field_ema_med_status/authorised-36/ema_medicine_types/field_ema_med_biosimilar/search_api_aggregation_ema_medicine_types/field_ema_med_biosimilar?sort=field_ema_med_market_auth_date&order=desc. Accessed September 24, 2021.